{"id":62610,"date":"2026-02-06T16:06:03","date_gmt":"2026-02-06T15:06:03","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/trubar-acquired-by-eti-gida-for-173-million-ushering-in-next-phase-of-global-growth\/"},"modified":"2026-02-06T16:06:03","modified_gmt":"2026-02-06T15:06:03","slug":"trubar-acquired-by-eti-gida-for-173-million-ushering-in-next-phase-of-global-growth","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/trubar-acquired-by-eti-gida-for-173-million-ushering-in-next-phase-of-global-growth\/","title":{"rendered":"TRUBAR Acquired by ETi G\u0131da for $173 Million, Ushering in Next Phase of Global Growth"},"content":{"rendered":"
\n

\nFounder and leadership team to remain in place as brand accelerates North American scale and international expansion<\/p>\n

MIAMI–(BUSINESS WIRE)–TRUBAR, the fast-growing protein bar brand known for its dessert-inspired flavors and clean ingredients, today announced the completion of its acquisition by ETi G\u0131da, a leading global snack company headquartered in Turkey (T\u00fcrkiye). Under the terms of the agreement, ETi G\u0131da acquired 100% of TRUBAR for $173 million in cash, with no earn-out.<\/p>\n

<\/a>
<\/a>
<\/a>
<\/a><\/p>\n

\nThe acquisition marks a pivotal moment in TRUBAR\u2019s growth trajectory, positioning the brand to scale further across North America while expanding into new international markets. TRUBAR\u2019s founder, leadership team, and employees will remain in place, continuing to operate the brand with the same vision, values, and mission that have driven its success to date.<\/p>\n

\n\u201cBy joining the ETi family, we\u2019re not changing who we are – we\u2019re doubling down on it,\u201d said Erica Groussman, Founder and CEO of TRUBAR. \u201cOur products, people, and values remain at the heart of everything we do. What changes is our ability to deliver with greater consistency, innovate faster, and reach more consumers around the world.\u201d<\/p>\n

\nFounded with a mission to create better-for-you snacks that don\u2019t compromise on taste, TRUBAR has built a loyal following through its high-quality ingredients, indulgent flavors, and playful, culture-forward branding. Consumers can expect continuity across TRUBAR\u2019s product lineup, partnerships, and day-to-day operations, now with the added benefits of ETi Gida\u2019s global scale and expertise.<\/p>\n

\nETi G\u0131da is a family-owned company that has been a leader in the global snack category for more than 65 years, recognized for its world-class manufacturing, deep consumer loyalty, and iconic brands. The partnership provides TRUBAR with significant resources to support continued growth in North America while accelerating expansion into new international markets.<\/p>\n

\n\u201cFor 65 years, ETi has built trusted snack brands grounded in quality, innovation, and deep consumer connection,\u201d said Firuzhan Kanatl\u0131, Chairman of the Board of ETi G\u0131da. \u201cWelcoming TRUBAR into the ETi family is a strategic step in expanding our presence in North America\u2014one of the most influential markets globally, shaping the future of snacking. By combining ETi\u2019s operational expertise and scale with TRUBAR\u2019s strong clean-label portfolio and agility, we believe both brands are well positioned for long-term global growth.<\/p>\n

\nFounded by my dear father Firuz Kanatl\u0131 together with my mother, and entrusted to my two sisters and me, ETi is a legacy we are committed to carrying into the future. Just as we have done for the past 65 years, we will continue for many more years to be a consumer-friendly brand worldwide, offering high-quality and trustworthy products.\u201d<\/p>\n

\n\u201cETi G\u0131da isn\u2019t just a snack company\u2014it\u2019s a brand people grow up with,\u201d Groussman added. \u201cFor generations it\u2019s been part of everyday moments that matter, creating an emotional connection rooted in happiness and trust. That idea of being \u2018the brand that comes to mind when people think of happiness\u2019 deeply resonates with me, and I\u2019m excited to bring that same spirit to TRUBAR as we expand our footprint globally.\u201d<\/p>\n

\nWith ETi G\u0131da\u2019s manufacturing capabilities, operational expertise, and global infrastructure, TRUBAR is uniquely positioned to unlock new growth opportunities while staying true to the brand DNA that made it successful.<\/p>\n

\nFounded in 2019, TRUBAR quickly emerged as a category disruptor, redefining what better-for-you snacking could look and taste like. Over the past year, the brand expanded its retail footprint to more than 21,000 locations. TRUBAR reached nearly $100 million in gross revenue in 2025, more than doubling the category\u2019s five-year growth rate. The company has also expanded its portfolio with the launch of TRUBAR Kids, bringing its mission to a new generation of consumers.<\/p>\n

\nFor more information, please visit: https:\/\/www.trubar.com\/<\/a>.<\/p>\n

\nAbout TRUBAR:<\/b><\/p>\n

\nTRUBAR is a female-founded brand redefining clean snacking with 100% plant-based, gluten-free, dairy-free, soy-free, and sugar alcohol-free protein bars. Designed for busy, health-conscious consumers, TRUBAR offers indulgent, dessert-inspired flavors that satisfy cravings without compromising on nutrition. TRUBAR is now available in 21,000+ retail locations, including Costco, Target, Whole Foods, Albertsons, and Erewhon, as well as on Amazon. With vibrant packaging, clean ingredients, and a commitment to quality, TRUBAR is proving that healthy snacking can be both delicious and nutritious. Follow @trubar.brands<\/a>. For more information, please visit: https:\/\/www.trubar.com\/<\/a>.<\/p>\n

\nAbout ETi:<\/b><\/p>\n

\nFounded in T\u00fcrkiye in 1961, ETi is a trusted, innovative, pioneering, and leading player in the food industry, distinguished by its deep-rooted heritage and strong corporate structure. At the time of its establishment, founder Firuz Kanatl\u0131 defined the company\u2019s purpose with the belief that \u201cThere is no higher purpose than happiness of humanity.\u201d This philosophy has since shaped ETi\u2019s corporate culture and values, forming the foundation of its identity.<\/p>\n

\nToday, ETi touches the lives of people around the world with nearly 8,500 employees and 9 production facilities. ETi leverages advanced technologies to manufacture a wide range of high-quality products, including biscuits, cakes, chocolate, savory snacks, wafers, functional and high-fiber products, breakfast foods, frozen foods, chilled snacks, gluten-free products, and baby foods. Supported by its highly advanced R&D centers, ETi sets industry standards and differentiates itself through continuous investments in technology.<\/p>\n

Contacts<\/b> <\/p>\n

\nPatricia Rogers | Patricia@TheTagExperience.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Founder and leadership team to remain in place as brand accelerates North American scale and international expansion MIAMI–(BUSINESS WIRE)–TRUBAR, the fast-growing protein bar brand known for its dessert-inspired flavors and clean ingredients, today announced the completion of its acquisition by ETi G\u0131da, a leading global snack company headquartered in Turkey (T\u00fcrkiye). Under the terms of … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62610","6":"format-standard","7":"category-industry"},"yoast_head":"\nTRUBAR Acquired by ETi G\u0131da for $173 Million, Ushering in Next Phase of Global Growth - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/trubar-acquired-by-eti-gida-for-173-million-ushering-in-next-phase-of-global-growth\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TRUBAR Acquired by ETi G\u0131da for $173 Million, Ushering in Next Phase of Global Growth - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Founder and leadership team to remain in place as brand accelerates North American scale and international expansion MIAMI–(BUSINESS WIRE)–TRUBAR, the fast-growing protein bar brand known for its dessert-inspired flavors and clean ingredients, today announced the completion of its acquisition by ETi G\u0131da, a leading global snack company headquartered in Turkey (T\u00fcrkiye). Under the terms of ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/trubar-acquired-by-eti-gida-for-173-million-ushering-in-next-phase-of-global-growth\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-06T15:06:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260206048638\/en\/2713464\/22\/ETIxTRUBAR.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/trubar-acquired-by-eti-gida-for-173-million-ushering-in-next-phase-of-global-growth\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/trubar-acquired-by-eti-gida-for-173-million-ushering-in-next-phase-of-global-growth\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"TRUBAR Acquired by ETi G\u0131da for $173 Million, Ushering in Next Phase of Global Growth\",\"datePublished\":\"2026-02-06T15:06:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/trubar-acquired-by-eti-gida-for-173-million-ushering-in-next-phase-of-global-growth\\\/\"},\"wordCount\":882,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/trubar-acquired-by-eti-gida-for-173-million-ushering-in-next-phase-of-global-growth\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260206048638\\\/en\\\/2713464\\\/22\\\/ETIxTRUBAR.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/trubar-acquired-by-eti-gida-for-173-million-ushering-in-next-phase-of-global-growth\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/trubar-acquired-by-eti-gida-for-173-million-ushering-in-next-phase-of-global-growth\\\/\",\"name\":\"TRUBAR Acquired by ETi G\u0131da for $173 Million, Ushering in Next Phase of Global Growth - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/trubar-acquired-by-eti-gida-for-173-million-ushering-in-next-phase-of-global-growth\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/trubar-acquired-by-eti-gida-for-173-million-ushering-in-next-phase-of-global-growth\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260206048638\\\/en\\\/2713464\\\/22\\\/ETIxTRUBAR.jpg\",\"datePublished\":\"2026-02-06T15:06:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/trubar-acquired-by-eti-gida-for-173-million-ushering-in-next-phase-of-global-growth\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/trubar-acquired-by-eti-gida-for-173-million-ushering-in-next-phase-of-global-growth\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/trubar-acquired-by-eti-gida-for-173-million-ushering-in-next-phase-of-global-growth\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260206048638\\\/en\\\/2713464\\\/22\\\/ETIxTRUBAR.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260206048638\\\/en\\\/2713464\\\/22\\\/ETIxTRUBAR.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/trubar-acquired-by-eti-gida-for-173-million-ushering-in-next-phase-of-global-growth\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TRUBAR Acquired by ETi G\u0131da for $173 Million, Ushering in Next Phase of Global Growth\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"TRUBAR Acquired by ETi G\u0131da for $173 Million, Ushering in Next Phase of Global Growth - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/trubar-acquired-by-eti-gida-for-173-million-ushering-in-next-phase-of-global-growth\/","og_locale":"en_US","og_type":"article","og_title":"TRUBAR Acquired by ETi G\u0131da for $173 Million, Ushering in Next Phase of Global Growth - Pharma Trend","og_description":"Founder and leadership team to remain in place as brand accelerates North American scale and international expansion MIAMI–(BUSINESS WIRE)–TRUBAR, the fast-growing protein bar brand known for its dessert-inspired flavors and clean ingredients, today announced the completion of its acquisition by ETi G\u0131da, a leading global snack company headquartered in Turkey (T\u00fcrkiye). Under the terms of ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/trubar-acquired-by-eti-gida-for-173-million-ushering-in-next-phase-of-global-growth\/","og_site_name":"Pharma Trend","article_published_time":"2026-02-06T15:06:03+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260206048638\/en\/2713464\/22\/ETIxTRUBAR.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/trubar-acquired-by-eti-gida-for-173-million-ushering-in-next-phase-of-global-growth\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/trubar-acquired-by-eti-gida-for-173-million-ushering-in-next-phase-of-global-growth\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"TRUBAR Acquired by ETi G\u0131da for $173 Million, Ushering in Next Phase of Global Growth","datePublished":"2026-02-06T15:06:03+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/trubar-acquired-by-eti-gida-for-173-million-ushering-in-next-phase-of-global-growth\/"},"wordCount":882,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/trubar-acquired-by-eti-gida-for-173-million-ushering-in-next-phase-of-global-growth\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260206048638\/en\/2713464\/22\/ETIxTRUBAR.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/trubar-acquired-by-eti-gida-for-173-million-ushering-in-next-phase-of-global-growth\/","url":"https:\/\/pharma-trend.com\/en\/trubar-acquired-by-eti-gida-for-173-million-ushering-in-next-phase-of-global-growth\/","name":"TRUBAR Acquired by ETi G\u0131da for $173 Million, Ushering in Next Phase of Global Growth - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/trubar-acquired-by-eti-gida-for-173-million-ushering-in-next-phase-of-global-growth\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/trubar-acquired-by-eti-gida-for-173-million-ushering-in-next-phase-of-global-growth\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260206048638\/en\/2713464\/22\/ETIxTRUBAR.jpg","datePublished":"2026-02-06T15:06:03+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/trubar-acquired-by-eti-gida-for-173-million-ushering-in-next-phase-of-global-growth\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/trubar-acquired-by-eti-gida-for-173-million-ushering-in-next-phase-of-global-growth\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/trubar-acquired-by-eti-gida-for-173-million-ushering-in-next-phase-of-global-growth\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260206048638\/en\/2713464\/22\/ETIxTRUBAR.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260206048638\/en\/2713464\/22\/ETIxTRUBAR.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/trubar-acquired-by-eti-gida-for-173-million-ushering-in-next-phase-of-global-growth\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"TRUBAR Acquired by ETi G\u0131da for $173 Million, Ushering in Next Phase of Global Growth"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62610","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62610"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62610\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62610"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62610"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62610"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}